Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237417 · ClinicalTrials.gov registry record · Phase 4
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
A Phase 4 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
NCT02237417 is a Phase 4 study that has completed, run by University of Utah. The registered enrollment target is 47 participants.
The verdict
NCT02237417, a Phase 4 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical and behavioral measures, and changes on magnetic resonance imaging (MRI) scans in subjects with schizophrenia compared with SOC oral antipsychotic medications and compared with a healthy control group.
Interventions
- OTHER No Treatment
- DRUG Standard of Care Oral antipsychotics
- DRUG IM aripiprazole once monthly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2014-09-01 |
| Est. Completion | 2020-07-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02237417
The ClinicalTrials.gov registry entry for NCT02237417 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which No Treatment is the first listed.
NCT02237417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02237417 about?
NCT02237417 is a clinical study titled "Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism". This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical and behavioral measures, and changes on magnetic resonance imaging (MRI...
What is the current status of trial NCT02237417?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2014-09-01. Estimated completion is 2020-07-30.
What interventions are being tested in trial NCT02237417?
The interventions under investigation include: No Treatment (OTHER), Standard of Care Oral antipsychotics (DRUG), IM aripiprazole once monthly (DRUG).
Who is sponsoring clinical trial NCT02237417?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.